TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
李章銘LEE, JANG-MING
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
11筆
1
Yang, P. W., Lin, M. C., Huang, P. M., Wang, C. P., Chen, T. C., Chen, C. N., Tsai, M. H., Cheng, J. C. H., Chuang, E. Y., Hsieh, M. S., Lou, P. J., & Lee, J. M. (2021). Risk Factors and Genetic Biomarkers of Multiple Primary Cancers in Esophageal Cancer Patients. Frontiers in Oncology, 10, Article 585621. https://doi.org/10.3389/fonc.2020.585621
2
Yang, P. W., Chang, Y. H., Wong, L. F., Lin, C. C., Huang, P. M., Hsieh, M. S., & Lee, J. M. (2021). The genetic effect and molecular function of the SOCS5 in the prognosis of esophageal squamous cell carcinoma. Journal of Cancer, 12(8), 2216-2229. https://doi.org/10.7150/jca.51806
3
Kao, T. N., Yang, P. W., Lin, M. W., & Lee, J. M. (2020). Induction therapy followed by surgery for advanced thymic tumors. Asian Journal of Surgery, 43(6), 707-708. https://doi.org/10.1016/j.asjsur.2020.01.008
4
Huang, Y. H., Chen, K. C., Lin, S. H., Huang, P. M., Yang, P. W., & Lee, J. M. (2020). Robotic-assisted single-incision gastric mobilization for minimally invasive oesophagectomy for oesophageal cancer: preliminary results. European Journal of Cardio-Thoracic Surgery, 58, 65-69. https://doi.org/10.1093/ejcts/ezaa212
5
Chen, J. X., Lu, T. Y., Fang, H. Y., Lin, Y. S., & Lee, J. M. (2020). The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation. World Journal of Surgery, 44(7), 2323-2331. https://doi.org/10.1007/s00268-020-05481-7
6
Lu, S. L., Hsu, F. M., Tsai, C. L., Lee, J. M., Huang, P. M., Hsu, C. H., . . . Cheng, J. C. H. (2019). Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. Ejso, 45(8), 1498-1504. doi:10.1016/j.ejso.2019.03.020
7
Yu, C. W., Chen, X. J., Lin, Y. H., Tseng, Y. H., Lu, C. C., Chen, B. B., . . . Shih, T. T. F. (2019). Prognostic value of F-18-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma. European Journal of Radiology, 120. doi:10.1016/j.ejrad.2019.108671
8
Huang, T. C., Lin, C. C., Wu, Y. C., Cheng, J. C. H., Lee, J. M., Wang, H. P., . . . Hsu, C. H. (2019). Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association, 118(6), 1024-1030. doi:10.1016/j.jfma.2018.11.003
9
Ma, W. L., Lin, C. C., Hsu, F. M., Lee, J. M., Chen, J. S., Hsieh, M. S., . . . Yang, J. C. H. (2019). Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. Clinical Lung Cancer, 20(6), E609-E618. doi:10.1016/j.cllc.2019.06.011
10
Yang, P. W., Liu, Y. C., Chang, Y. H., Lin, C. C., Huang, P. M., Hua, K. T., . . . Hsieh, M. S. (2019). Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC). Frontiers in Oncology, 9. doi:10.3389/fonc.2019.01138
1
2
